NEXGEL

NEXGEL is a commercial-stage medical device and drug delivery company leveraging its proprietary electron-beam cross-linked hydrogel platform. Its technology enables the gentle, transdermal delivery of a wide array of OTC, cosmetic, and natural compounds, targeting markets in beauty, foot care, pain relief, and wound management. With a 16,500 sq. ft. integrated R&D and manufacturing facility, the company serves both large corporate clients and startups through custom formulation and contract manufacturing. NEXGEL is a public company, positioning itself as a flexible partner in the growing transdermal patch market.

Proprietary electron-beam cross-linked hydrogel platform for transdermal delivery. Creates gentle, high-water-content patches without chemical cross-linkers or adhesives. Includes formulations with varying water content (55%-94.5%) and adhesion for different applications (Arctic5, Arctic10, Synapse, Mother Earth).

NEXGEL competes with larger medical device companies offering traditional adhesive transdermal patches (e.g., 3M, Hisamitsu) and other hydrogel developers. Its differentiation lies in its gentle, e-beam cross-linked, non-adhesive technology and its integrated CDMO capabilities for customization, though it lacks the scale and brand recognition of major players.